RENX vs. KOO, COG, INHC, FDBK, IQAI, TRLS, DVRG, SENS, EMIS, and CRW
Should you be buying Renalytix stock or one of its competitors? The main competitors of Renalytix include Kooth (KOO), Cambridge Cognition (COG), Induction Healthcare Group (INHC), Feedback (FDBK), IQ-AI (IQAI), Trellus Health (TRLS), DeepVerge (DVRG), Sensyne Health (SENS), EMIS Group (EMIS), and Craneware (CRW). These companies are all part of the "health information services" industry.
Renalytix vs. Its Competitors
Renalytix (LON:RENX) and Kooth (LON:KOO) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, profitability, dividends, analyst recommendations, risk, media sentiment and institutional ownership.
Kooth has a net margin of 7.89% compared to Renalytix's net margin of -1,191.75%. Renalytix's return on equity of 293.20% beat Kooth's return on equity.
28.4% of Renalytix shares are owned by institutional investors. Comparatively, 65.0% of Kooth shares are owned by institutional investors. 35.7% of Renalytix shares are owned by company insiders. Comparatively, 17.3% of Kooth shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
In the previous week, Kooth had 1 more articles in the media than Renalytix. MarketBeat recorded 1 mentions for Kooth and 0 mentions for Renalytix. Kooth's average media sentiment score of 0.67 beat Renalytix's score of 0.00 indicating that Kooth is being referred to more favorably in the news media.
Renalytix has a beta of 2.1, meaning that its share price is 110% more volatile than the S&P 500. Comparatively, Kooth has a beta of 0.71, meaning that its share price is 29% less volatile than the S&P 500.
Kooth has higher revenue and earnings than Renalytix. Renalytix is trading at a lower price-to-earnings ratio than Kooth, indicating that it is currently the more affordable of the two stocks.
Kooth has a consensus price target of GBX 456.67, suggesting a potential upside of 189.03%. Given Kooth's stronger consensus rating and higher probable upside, analysts plainly believe Kooth is more favorable than Renalytix.
Summary
Kooth beats Renalytix on 12 of the 16 factors compared between the two stocks.
Get Renalytix News Delivered to You Automatically
Sign up to receive the latest news and ratings for RENX and its competitors with MarketBeat's FREE daily newsletter.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Renalytix Competitors List
Related Companies and Tools
This page (LON:RENX) was last updated on 8/23/2025 by MarketBeat.com Staff
MarketBeat All Access